{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T06:59:52Z","timestamp":1715669992425},"reference-count":83,"publisher":"IntechOpen","isbn-type":[{"value":"9781803560922","type":"print"},{"value":"9781803560939","type":"electronic"}],"license":[{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>The recent availability of several lines of novel therapeutic agents such as immunomodulatory agents, proteasome inhibitors, and monoclonal antibodies; the widespread utilization of hematopoietic stem cell transplantation; the use of advanced diagnostic techniques that allow risk stratification and monitoring of treatment responses; and the general improvement in health care have revolutionized treatment of patients with multiple myeloma and this has translated into significant improvements in survival outcomes. Monitoring of minimal residual disease can guide the intensity of treatment, and the efficient application of modern diagnostic tools in monitoring treatment responses in real-world clinical practice can hopefully be achieved in the near future. The recent use of quadruplet regimens in the treatment of patients with multiple myeloma has translated into unprecedented treatment responses and survival outcomes. Also, chimeric antigen receptor T-cell therapy and bispecific antibodies represent a new dimension in the precision medicine in MM. Additionally, our ability to induce deep responses has improved, and the treatment goal in myeloma patients tolerating the recommended therapy has moved from delay of disease progression to induction of the deepest possible response.<\/jats:p>","DOI":"10.5772\/intechopen.109279","type":"book-chapter","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T14:54:31Z","timestamp":1674226471000},"source":"Crossref","is-referenced-by-count":0,"title":["Multiple Myeloma in the Era of Novel Agents and Stem Cell Therapies"],"prefix":"10.5772","author":[{"given":"Khalid","family":"Ahmed Al-Anazi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3774","published-online":{"date-parts":[[2023,3,15]]},"reference":[{"key":"ref=1","doi-asserted-by":"crossref","unstructured":"Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. American Journal of Hematology. 2022;97(8):1086-1107. DOI: 10.1002\/ajh.26590. Epub: 23 May 2022","DOI":"10.1002\/ajh.26590"},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Charli\u0144ski G, Jurczyszyn A. Multiple myeloma-2020 update on diagnosis and management. NOWOTWORY Journal of Oncology. 2020;70:173-183. DOI: 10.5603\/ NJO.a2020.0035","DOI":"10.5603\/NJO.a2020.0035"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, et al. Epidemiology, staging, and management of multiple myeloma. Medical Sciences (Basel). 2021;9(1):3. DOI: 10.3390\/ medsci9010003","DOI":"10.3390\/medsci9010003"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Jurczyszyn A, Suska A. Multiple myeloma. Encyclopedia in Biomedical Gerontology. 2020;2:461-478. DOI: 10.1016\/B978-0-12-801238-3.11412-6. Epub: 29 Nov 2019","DOI":"10.1016\/B978-0-12-801238-3.11412-6"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"Gerecke C, Fuhrmann S, Strifler S, Schmidt-Hieber M, Einsele H, Knop S. The diagnosis and treatment of multiple myeloma. Deutsches \u00c4rzteblatt International. 2016;113(27-28):470-476. DOI: 10.3238\/arztebl.2016. 0470","DOI":"10.3238\/arztebl.2016.0470"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390. DOI: 10.1182\/blood-2016-01-643569. Epub: 15 Mar 2016","DOI":"10.1182\/blood-2016-01-643569"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"B\u0119bnowska D, Hrynkiewicz R, Grywalska E, Pasiarski M, Sosnowska-Pasiarska B, Smarz-Widelska I, et al. Immunological prognostic factors in multiple myeloma. International Journal of Molecular Sciences. 2021;22(7):3587. DOI: 10.3390\/ijms22073587","DOI":"10.3390\/ijms22073587"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Qian J, Jin J, Luo H, Jin C, Wang L, Qian W, et al. Analysis of clinical characteristics and prognostic factors of multiple myeloma: A retrospective single-center study of 787 cases. Hematology. 2017;22(8):472-476. DOI: 10.1080\/10245332.2017.1309493. Epub: 2 May 2017","DOI":"10.1080\/10245332.2017.1309493"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): A randomised, open-label, phase 3 trial. Lancet. 2017;389(10068):519-527. DOI: 10.1016\/ S0140-6736(16)31594-X. Epub: 23 Dec 2016","DOI":"10.1016\/S0140-6736(16)31594-X"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Kazandjian D. Multiple myeloma epidemiology and survival: A unique malignancy. Seminars in Oncology. 2016;43(6):676-681. DOI: 10.1053\/ j.seminoncol.2016.11.004. Epub: 10 Nov 2016","DOI":"10.1053\/j.seminoncol.2016.11.004"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"Joshua DE, Bryant C, Dix C, Gibson J, Ho J. Biology and therapy of multiple myeloma. The Medical Journal of Australia. 2019;210(8):375-380. DOI: 10.5694\/mja2.50129. Epub: 23 Apr 2019","DOI":"10.5694\/mja2.50129"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Rajkumar SV. Updated diagnostic criteria and staging system for multiple myeloma. American Society of Clinical Oncology Educational Book. 2016;35:e418-e423. DOI: 10.1200\/EDBK_159009","DOI":"10.1200\/EDBK_159009"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: A report from International Myeloma Working Group. Journal of Clinical Oncology. 2015;33(26):2863-2869. DOI: 10.1200\/JCO.2015.61.2267. Epub: 3 Aug 2015","DOI":"10.1200\/JCO.2015.61.2267"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Pinto V, Bergantim R, Caires HR, Seca H, Guimar\u00e3es JE, Vasconcelos MH. Multiple myeloma: Available therapies and causes of drug resistance. Cancers (Basel). 2020;12(2):407. DOI: 10.3390\/cancers12020407","DOI":"10.3390\/cancers12020407"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"Offidani M, Corvatta L, Mor\u00e8 S, Olivieri A. Novel experimental drugs for treatment of multiple myeloma. Journal of Experimental Pharmacology. 2021;13:245-264. DOI: 10.2147\/JEP.S265288","DOI":"10.2147\/JEP.S265288"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"Yang Y, Li Y, Gu H, Dong M, Cai Z. Emerging agents and regimens for multiple myeloma. Journal of Hematology & Oncology. 2020;13(1):150. DOI: 10.1186\/s13045-020-00980-5","DOI":"10.1186\/s13045-020-00980-5"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"Gulla A, Anderson KC. Multiple myeloma: The revolution of current therapy and a glance into future. Haematologica. 2020;105(10):2358-2367. DOI: 10.3324\/haematol.2020.247015","DOI":"10.3324\/haematol.2020.247015"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"Leow CC, Low MSY. Targeted therapies for multiple myeloma. Journal of Persian Medicine. 2021;11(5):334. DOI: 10.3390\/jpm11050334","DOI":"10.3390\/jpm11050334"},{"key":"ref=19","unstructured":"Al-Anazi KA. Hematopoietic stem cell transplantation in multiple myeloma in the era of novel therapies. In: Al-Anazi KA, editor. Update on Multiple Myeloma. London, UK: Intech Open; 5 Nov 2018. DOI: 10.5772\/ intechopen.79999"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"Caro J, Al Hadidi S, Usmani S, Yee AJ, Raje N, Davies FE. How to treat high-risk myeloma at diagnosis and relapse. American Society of Clinical Oncology Educational Book. 2021;41:291-309. DOI: 10.1200\/ EDBK_320105","DOI":"10.1200\/EDBK_320105"},{"key":"ref=21","doi-asserted-by":"crossref","unstructured":"Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, et al. International Myeloma Working Group consensus on risk stratification in multiple myeloma. Leukemia. 2014;28(2):269-277. DOI: 10.1038\/leu.2013.247. Epub: 26 Aug 2013","DOI":"10.1038\/leu.2013.247"},{"key":"ref=22","doi-asserted-by":"crossref","unstructured":"Perrot A, Corre J, Avet-Loiseau H. Risk stratification and targets in multiple myeloma: From genomics to the bedside. American Society of Clinical Oncology Educational Book. 2018;38:675-680. DOI: 10.1200\/EDBK_200879","DOI":"10.1200\/EDBK_200879"},{"key":"ref=23","doi-asserted-by":"crossref","unstructured":"Hanamura I. Multiple myeloma with high-risk cytogenetics and its treatment approach. International Journal of Hematology. 2022;115(6):762-777. DOI: 10.1007\/s12185-022-03353-5. Epub: 9 May 2022","DOI":"10.1007\/s12185-022-03353-5"},{"key":"ref=24","doi-asserted-by":"crossref","unstructured":"Marneni N, Chakraborty R. Current approach to managing patients with newly diagnosed high-risk multiple myeloma. Current Hematologic Malignancy Reports. 2021;16(2):148-161. DOI: 10.1007\/s11899-021-00631-7. Epub: 19 Apr 2021","DOI":"10.1007\/s11899-021-00631-7"},{"key":"ref=25","doi-asserted-by":"crossref","unstructured":"Woldu M, Fentie A, Tadesse T. Treatment approaches of multiple myeloma. In: Fuchs O, editor. Multiple Myeloma. London: Intech Open; 6 May 2021. DOI: 10.5772\/intechopen.97390.","DOI":"10.5772\/intechopen.97390"},{"key":"ref=26","doi-asserted-by":"crossref","unstructured":"L\u00ea GN, Bones J, Coyne M, Bazou D, Dowling P, O\u2019Gorman P, et al. Current and future biomarkers for risk-stratification and treatment personalisation in multiple myeloma. Molecular Omics. 2019;15(1):7-20. DOI: 10.1039\/c8mo00193f","DOI":"10.1039\/C8MO00193F"},{"key":"ref=27","doi-asserted-by":"crossref","unstructured":"Hanbali A, Hassanein M, Rasheed W, Aljurf M, Alsharif F. The evolution of prognostic factors in multiple myeloma. Advances in Hematology. 2017;2017:4812637. DOI: 10.1155\/2017\/4812637. Epub: 21 Feb 2017","DOI":"10.1155\/2017\/4812637"},{"key":"ref=28","doi-asserted-by":"crossref","unstructured":"Pawlyn C, Davies FE. Toward personalized treatment in multiple myeloma based on molecular characteristics. Blood. 2019;133(7):660-675. DOI: 10.1182\/blood-2018-09-825331. Epub: 26 Dec 2018","DOI":"10.1182\/blood-2018-09-825331"},{"key":"ref=29","doi-asserted-by":"crossref","unstructured":"Fonseca R, Monge J, Dimopoulos MA. Staging and prognostication of multiple myeloma. Expert Reviews of Hematology. 2014;7(1):21-31. DOI 10.1586\/17474086.2014.882224","DOI":"10.1586\/17474086.2014.882224"},{"key":"ref=30","doi-asserted-by":"crossref","unstructured":"Ho M, Bianchi G, Anderson KC. Proteomics-inspired precision medicine for treating and understanding multiple myeloma. Expert Review of Precision Medicine Drug Development. 2020;5(2):67-85. DOI: 10.1080\/23808993.2020.1732205. Epub: 24 Feb 2020","DOI":"10.1080\/23808993.2020.1732205"},{"key":"ref=31","doi-asserted-by":"crossref","unstructured":"Han W, Jin Y, Xu M, Zhao SS, Shi Q, Qu X, et al. Prognostic value of circulating clonal plasma cells in newly diagnosed multiple myeloma. Hematology. 2021;26(1):510-517. DOI: 10.1080\/16078454.2021.1948208","DOI":"10.1080\/16078454.2021.1948208"},{"key":"ref=32","doi-asserted-by":"crossref","unstructured":"Galieni P, Travaglini F, Vagnoni D, Ruggieri M, Caraffa P, Bigazzi C, et al. The detection of circulating plasma cells may improve the Revised International Staging System (R-ISS) risk stratification of patients with newly diagnosed multiple myeloma. British Journal of Haematology. 2021;193(3):542-550. DOI: 10.1111\/bjh.17118. Epub: 1 Apr 2021","DOI":"10.1111\/bjh.17118"},{"key":"ref=33","doi-asserted-by":"crossref","unstructured":"Mack EKM, Hartmann S, Ross P, Wollmer E, Mann C, Neubauer A, et al. Monitoring multiple myeloma in the peripheral blood based on cell-free DNA and circulating plasma cells. Annals of Hematology. 2022;101(4):811-824. DOI: 10.1007\/ s00277-022-04771-5. Epub: 1 Feb 2022","DOI":"10.1007\/s00277-022-04771-5"},{"key":"ref=34","doi-asserted-by":"crossref","unstructured":"Sanoja-Flores L, Flores-Montero J, Puig N, Contreras-Sanfeliciano T, Pontes R, Corral-Mateos A, et al. Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy. Blood. 2019;134(24):2218-2222. DOI: 10.1182\/blood.2019002610","DOI":"10.1182\/blood.2019002610"},{"key":"ref=35","doi-asserted-by":"crossref","unstructured":"Sanoja-Flores L, Flores-Montero J, Garc\u00e9s JJ, Paiva B, Puig N, Garc\u00eda-Mateo A, et al. Euroflow consortium. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). Blood Cancer Journal. 2018;8(12):117. DOI: 10.1038\/s41408-018-0153-9","DOI":"10.1038\/s41408-018-0153-9"},{"key":"ref=36","doi-asserted-by":"crossref","unstructured":"Rustad EH, Coward E, Skyt\u00f8en ER, Misund K, Holien T, Standal T, et al. Monitoring multiple myeloma by quantification of recurrent mutations in serum. Haematologica. 2017;102(7):1266-1272. DOI: 10.3324\/haematol.2016.160564. Epub: 6 Apr 2017","DOI":"10.3324\/haematol.2016.160564"},{"key":"ref=37","doi-asserted-by":"crossref","unstructured":"Yasui H, Kobayashi M, Sato K, Kondoh K, Ishida T, Kaito Y, et al. Circulating cell-free DNA in the peripheral blood plasma of patients is an informative biomarker for multiple myeloma relapse. International Journal of Clinical Oncology. 2021;26(11):2142-2150. DOI: 10.1007\/s10147-021-01991-z. Epub: 14 Jul 2021","DOI":"10.1007\/s10147-021-01991-z"},{"key":"ref=38","doi-asserted-by":"crossref","unstructured":"Manier S, Park J, Capelletti M, Bustoros M, Freeman SS, Ha G, et al. Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma. Nature Communications. 2018;9(1):1691. DOI: 10.1038\/s41467-018-04001-5","DOI":"10.1038\/s41467-018-04001-5"},{"key":"ref=39","doi-asserted-by":"crossref","unstructured":"Deshpande S, Tytarenko RG, Wang Y, Boyle EM, Ashby C, Schinke CD, et al. Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA. European Journal of Haematology. 2021;106(2):230-240. DOI: 10.1111\/ ejh.13541. Epub: 10 Nov 2020","DOI":"10.1111\/ejh.13541"},{"key":"ref=40","doi-asserted-by":"crossref","unstructured":"Chen X, Liu L, Chen M, Xiang J, Wan Y, Li X, et al. A five-gene risk score model for predicting the prognosis of multiple myeloma patients based on gene expression profiles. Frontiers in Genetics. 2021;12:785330. DOI: 10.3389\/fgene.2021.785330","DOI":"10.3389\/fgene.2021.785330"},{"key":"ref=41","doi-asserted-by":"crossref","unstructured":"Qi T, Qu J, Tu C, Lu Q, Li G, Wang J, et al. Super-enhancer associated five-gene risk score model predicts overall survival in multiple myeloma patients. Frontiers in Cell and Developmental Biology. 2020;8:596777. DOI: 10.3389\/fcell.2020. 596777","DOI":"10.3389\/fcell.2020.596777"},{"key":"ref=42","doi-asserted-by":"crossref","unstructured":"Liu L, Qu J, Dai Y, Qi T, Teng X, Li G, et al. An interactive nomogram based on clinical and molecular signatures to predict prognosis in multiple myeloma patients. Aging (Albany NY). 2021;13(14):18442-18463. DOI: 0.18632\/aging.203294. Epub: 14 Jul 2021","DOI":"10.18632\/aging.203294"},{"key":"ref=43","doi-asserted-by":"crossref","unstructured":"Mina R, Oliva S, Boccadoro M. Minimal residual disease in multiple myeloma: State of the art and future perspectives. Journal of Clinical Medicine. 2020;9(7):2142. DOI: 10.3390\/ jcm9072142","DOI":"10.3390\/jcm9072142"},{"key":"ref=44","doi-asserted-by":"crossref","unstructured":"Oliva S, D\u2019Agostino M, Boccadoro M, Larocca A. Clinical applications and future directions of minimal residual disease testing in multiple myeloma. Frontiers in Oncology. 2020;10:1. DOI: 10.3389\/fonc.2020. 00001","DOI":"10.3389\/fonc.2020.00001"},{"key":"ref=45","doi-asserted-by":"crossref","unstructured":"Bertamini L, D\u2019Agostino M, Gay F. MRD assessment in multiple myeloma: Progress and challenges. Current Hematologic Malignancy Reports. 2021;16(2):162-171. DOI: 10.1007\/ s11899-021-00633-5. Epub: 5 May 2021","DOI":"10.1007\/s11899-021-00633-5"},{"key":"ref=46","doi-asserted-by":"crossref","unstructured":"Bonello F, Cani L, D\u2019Agostino M. Risk stratification before and during treatment in newly diagnosed multiple myeloma: From clinical trials to the real-world setting. Frontiers in Oncology. 2022;12:830922. DOI: 10.3389\/fonc.2022. 830922","DOI":"10.3389\/fonc.2022.830922"},{"key":"ref=47","doi-asserted-by":"crossref","unstructured":"Rajkumar SV. Multiple myeloma: Every year a new standard? Hematological Oncology. 2019;37(Suppl. 1):62-65. DOI: 10.1002\/hon.2586","DOI":"10.1002\/hon.2586"},{"key":"ref=48","doi-asserted-by":"crossref","unstructured":"Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, et al. Management of relapsed and refractory multiple myeloma: Novel agents, antibodies, immunotherapies and beyond. Leukemia. 2018;32(2):252-262. DOI: 10.1038\/leu. 2017.329. Epub: 16 Nov 2017","DOI":"10.1038\/leu.2017.329"},{"key":"ref=49","doi-asserted-by":"crossref","unstructured":"Sanchez L, Barley K, Richter J, Franz J, Cho HJ, Jagannath S, et al. Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: An evidence-based review. Expert Reviews of Hematology. 2020;13(9):943-958. DOI: 10.1080\/17474086.2020.1804356. Epub: 30 Aug 2020","DOI":"10.1080\/17474086.2020.1804356"},{"key":"ref=50","doi-asserted-by":"crossref","unstructured":"Zheng Y, Shen H, Xu L, Feng J, Tang H, Zhang N, et al. Monoclonal antibodies versus histone deacetylase inhibitors in combination with bortezomib or lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: An indirect-comparison meta-analysis of randomized controlled trials. Journal of Immunology Research. 2018;2018:7646913. DOI: 10.1155\/2018\/7646913","DOI":"10.1155\/2018\/7646913"},{"key":"ref=51","doi-asserted-by":"crossref","unstructured":"Ye W, Wu X, Liu X, Zheng X, Deng J, Gong Y. Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1\/PD-L1 in combination with bortezomib\/immunomodulators plus dexamethasone\/ prednisone for the treatment of multiple myeloma: An indirect-comparison meta-analysis of randomised controlled trials. BMC Cancer. 2021;21(1):994. DOI: 10.1186\/s12885-021-08588-9","DOI":"10.1186\/s12885-021-08588-9"},{"key":"ref=52","doi-asserted-by":"crossref","unstructured":"Kawaji-Kanayama Y, Kobayashi T, Muramatsu A, Uchiyama H, Sasaki N, Uoshima N, et al. Kyoto Clinical Hematology Study Group (KOTOSG) Investigators. Prognostic impact of resistance to bortezomib and\/or lenalidomide in carfilzomib-based therapies for relapsed\/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients. Cancer Report (Hoboken). 2022;5(2):e1476. DOI: 10.1002\/cnr2.1476. Epub: 14 Jun 2021","DOI":"10.1002\/cnr2.1476"},{"key":"ref=53","doi-asserted-by":"crossref","unstructured":"Mele A, Prete E, De Risi C, Citiso S, Greco G, Falcone AP, et al. Carfilzomib, lenalidomide, and dexamethasone in relapsed\/refractory multiple myeloma patients: The real-life experience of Rete Ematologica Pugliese (REP). Annals of Hematology. 2021;100(2):429-436. DOI: 10.1007\/s00277-020-04329-3. Epub: 7 Nov 2020","DOI":"10.1007\/s00277-020-04329-3"},{"key":"ref=54","doi-asserted-by":"crossref","unstructured":"Rocchi S, Tacchetti P, Pantani L, Mancuso K, Rizzello I, di Giovanni BC, et al. A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed\/refractory multiple myeloma. Hematological Oncology. 2021;39(1):41-50. DOI: 10.1002\/hon.2820. Epub: 1 Nov 2020","DOI":"10.1002\/hon.2820"},{"key":"ref=55","doi-asserted-by":"crossref","unstructured":"Atrash S, Thompson-Leduc P, Tai MH, Kaila S, Gray K, Ghelerter I, et al. Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: A real-world chart review study. BMC Cancer. 2021;21(1):1207. DOI: 10.1186\/s12885-021-08881-7","DOI":"10.1186\/s12885-021-08881-7"},{"key":"ref=56","doi-asserted-by":"crossref","unstructured":"Zhang T, Wang S, Lin T, Xie J, Zhao L, Liang Z, et al. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed\/refractory multiple myeloma. Oncotarget. 2017;8(20):34001-34017. DOI: 10.18632\/oncotarget.16987","DOI":"10.18632\/oncotarget.16987"},{"key":"ref=57","doi-asserted-by":"crossref","unstructured":"Richard S, Jagannath S, Cho HJ, Parekh S, Madduri D, Richter J, et al. A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed\/refractory multiple myeloma. Expert Review of Hematology. 2021;14(1):31-45. DOI: 10.1080\/17474086.2021.1858790. Epub: 17 Dec 2020","DOI":"10.1080\/17474086.2021.1858790"},{"key":"ref=58","doi-asserted-by":"crossref","unstructured":"Mikhael J. Treatment options for triple-class refractory multiple myeloma. Clinical Lymphoma, Myeloma & Leukemia. 2020;20(1):1-7. DOI: 10.1016\/j.clml.2019.09.621. Epub: 9 Oct 2019","DOI":"10.1016\/j.clml.2019.09.621"},{"key":"ref=59","doi-asserted-by":"crossref","unstructured":"Costa LJ, Hungria V, Mohty M, Mateos MV. How I treat triple-class refractory multiple myeloma. British Journal of Haematology. 2022;198(2):244-256. DOI: 10.1111\/bjh.18185. Epub: 3 Apr 2022","DOI":"10.1111\/bjh.18185"},{"key":"ref=60","doi-asserted-by":"crossref","unstructured":"Baertsch MA, Fougereau M, Hielscher T, Sauer S, Breitkreutz I, Jordan K, et al. Carfilzomib, lenalidomide, and dexamethasone followed by salvage autologous stem cell transplant with or without maintenance for relapsed or refractory multiple myeloma. Cancers (Basel). 2021;13(18):4706. DOI: 10.3390\/cancers13184706","DOI":"10.3390\/cancers13184706"},{"key":"ref=61","doi-asserted-by":"crossref","unstructured":"Li J, Tang Y, Huang Z. Efficacy and safety of chimeric antigen receptor (CAR)-T cell therapy in the treatment of relapsed and refractory multiple myeloma: A systematic-review and meta-analysis of clinical trials. Translational Cancer Research. 2022;11(3):569-579. DOI: 10.21037\/tcr-22-344","DOI":"10.21037\/tcr-22-344"},{"key":"ref=62","doi-asserted-by":"crossref","unstructured":"Yang Q, Li X, Zhang F, Yang Q, Zhou W, Liu J. Efficacy and safety of CAR-T therapy for relapse or refractory multiple myeloma: A systematic review and meta-analysis. International Journal of Medical Sciences. 2021;18(8):1786-1797. DOI: 10. 7150\/ ijms.46811","DOI":"10.7150\/ijms.46811"},{"key":"ref=63","doi-asserted-by":"crossref","unstructured":"Deng H, Liu M, Yuan T, Zhang H, Cui R, Li J, et al. Efficacy of humanized anti-BCMA CAR T cell therapy in relapsed\/refractory multiple myeloma patients with and without extramedullary disease. Frontiers in Immunology. 2021;12:720571. DOI: 10.3389\/fimmu.2021.720571","DOI":"10.3389\/fimmu.2021.720571"},{"key":"ref=64","doi-asserted-by":"crossref","unstructured":"Zhang L, Shen X, Yu W, Li J, Zhang J, Zhang R, et al. Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma. Annals of Medicine. 2021;53(1):1547-1559. DOI: 10.1080\/ 07853890. 2021.1970218","DOI":"10.1080\/07853890.2021.1970218"},{"key":"ref=65","doi-asserted-by":"crossref","unstructured":"Mei H, Li C, Jiang H, Zhao X, Huang Z, Jin D, et al. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. Journal of Hematology & Oncology. 2021;14(1):161. DOI: 10.1186\/s13045-021-01170-7","DOI":"10.1186\/s13045-021-01170-7"},{"key":"ref=66","doi-asserted-by":"crossref","unstructured":"Swan D, Routledge D, Harrison S. The evolving status of immunotherapies in multiple myeloma: The future role of bispecific antibodies. British Journal of Haematology. 2022;196(3):488-506. DOI: 10.1111\/ bjh.17805. Epub: 1 Sep 2021","DOI":"10.1111\/bjh.17805"},{"key":"ref=67","doi-asserted-by":"crossref","unstructured":"Lancman G, Sastow DL, Cho HJ, Jagannath S, Madduri D, Parekh SS, et al. Bispecific antibodies in multiple myeloma: Present and future. Blood Cancer Discovery. 2021;2(5):423-433. DOI: 10.1158\/2643-3230.BCD-21-0028","DOI":"10.1158\/2643-3230.BCD-21-0028"},{"key":"ref=68","doi-asserted-by":"crossref","unstructured":"Zhou X, Einsele H, Danhof S. Bispecific antibodies: A new era of treatment for multiple myeloma. Journal of Clinical Medicine. 2020;9(7):2166. DOI: 10.3390\/jcm9072166","DOI":"10.3390\/jcm9072166"},{"key":"ref=69","doi-asserted-by":"crossref","unstructured":"Hosny M, Verkleij CPM, van der Schans J, Frerichs KA, Mutis T, Zweegman S, et al. Current state of the art and prospects of T cell-redirecting bispecific antibodies in multiple myeloma. Journal of Clinical Medicine. 2021;10(19):4593. DOI: 10.3390\/ jcm10194593","DOI":"10.3390\/jcm10194593"},{"key":"ref=70","doi-asserted-by":"crossref","unstructured":"Vogl DT, Dingli D, Cornell RF, Huff CA, Jagannath S, Bhutani D, et al. Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma. Journal of Clinical Oncology. 2018;36(9):859-866. DOI: 10.1200\/JCO.2017.75.5207. Epub: 30 Jan 2018","DOI":"10.1200\/JCO.2017.75.5207"},{"key":"ref=71","doi-asserted-by":"crossref","unstructured":"Bahlis NJ, Sutherland H, White D, Sebag M, Lentzsch S, Kotb R, et al. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma. Blood. 2018;132(24):2546-2554. DOI: 10.1182\/blood-2018-06-858852. Epub: 23 Oct 2018","DOI":"10.1182\/blood-2018-06-858852"},{"key":"ref=72","doi-asserted-by":"crossref","unstructured":"Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. The New England Journal of Medicine. 2019;381(8):727-738. DOI: 10.1056\/ NEJMoa1903455","DOI":"10.1056\/NEJMoa1903455"},{"key":"ref=73","doi-asserted-by":"crossref","unstructured":"Grosicki S, Simonova M, Spicka I, Pour L, Kriachok I, Gavriatopoulou M, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): A randomised, open-label, phase 3 trial. Lancet. 2020;396(10262):1563-1573. DOI: 10.1016\/S0140-6736(20)32292-3","DOI":"10.1016\/S0140-6736(20)32292-3"},{"key":"ref=74","doi-asserted-by":"crossref","unstructured":"Peterson TJ, Orozco J, Buege M. Selinexor: A first-in-class nuclear export inhibitor for management of multiply relapsed multiple myeloma. The Annals of Pharmacotherapy. 2020;54(6):577-582. DOI: 10.1177\/1060028019892643. Epub: 2 Dec 2019","DOI":"10.1177\/1060028019892643"},{"key":"ref=75","doi-asserted-by":"crossref","unstructured":"Ehsan H, Wahab A, Shah Z, Sana MK, Masood A, Rafae A, et al. Role of Venetoclax in the treatment of relapsed and refractory multiple myeloma. Journal of Hematology. 2021;10(3):89-97. DOI: 10.14740\/ jh844. Epub: 16 Jun 2021","DOI":"10.14740\/jh844"},{"key":"ref=76","doi-asserted-by":"crossref","unstructured":"Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): A randomised, double-blind, multicentre, phase 3 trial. The Lancet Oncology. 2020;21(12):1630-1642. DOI: 10.1016\/S1470-2045(20)30525-8. Epub: 29 Oct 2020","DOI":"10.1016\/S1470-2045(20)30525-8"},{"key":"ref=77","doi-asserted-by":"crossref","unstructured":"Kaufman JL, Gasparetto C, Schjesvold FH, Moreau P, Touzeau C, Facon T, et al. Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed\/refractory t(11;14) multiple myeloma. American Journal of Hematology. 2021;96(4):418-427. DOI: 10.1002\/ajh.26083. Epub: 19 Jan 2021","DOI":"10.1002\/ajh.26083"},{"key":"ref=78","doi-asserted-by":"crossref","unstructured":"Gooding S, Ansari-Pour N, Towfic F, Ortiz Est\u00e9vez M, Chamberlain PP, Tsai KT, et al. Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma. Blood. 2021;137(2):232-237. DOI: 10.1182\/blood.2020007081","DOI":"10.1182\/blood.2020007081"},{"key":"ref=79","doi-asserted-by":"crossref","unstructured":"Thakurta A, Pierceall WE, Amatangelo MD, Flynt E, Agarwal A. Developing next generation immunomodulatory drugs and their combinations in multiple myeloma. Oncotarget. 2021;12(15):1555-1563. DOI: 10.18632\/oncotarget.27973","DOI":"10.18632\/oncotarget.27973"},{"key":"ref=80","doi-asserted-by":"crossref","unstructured":"Bjorklund CC, Kang J, Amatangelo M, Polonskaia A, Katz M, Chiu H, et al. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN. Leukemia. 2020;34(4):1197-1201. DOI: 10.1038\/s41375-019-0620-8. Epub: 12 Nov 2019","DOI":"10.1038\/s41375-019-0620-8"},{"key":"ref=81","doi-asserted-by":"crossref","unstructured":"Lonial S, Richardson PG, Popat R, Stadtmauer EA, Larsen JT, Oriol A, et al. OAB-013: Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM). Clinical Lymphoma, Myeloma & Leukemia. 2021;21(Suppl 2):S9. DOI: 10.1016\/ S2152-2650(21)02087-5","DOI":"10.1016\/S2152-2650(21)02087-5"},{"key":"ref=82","doi-asserted-by":"crossref","unstructured":"Kapoor P, Gonsalves WI. Melflufen for multiple myeloma: A promise unfulfilled? Lancet Haematology. 2022;9(2):e82-e84. DOI: 10.1016\/ S2352-3026(22)00002-3. Epub: 12 Jan 2022","DOI":"10.1016\/S2352-3026(22)00002-3"},{"key":"ref=83","doi-asserted-by":"crossref","unstructured":"Olivier T, Prasadb V. The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA. Translational Oncology. 2022;18:101374. DOI: 10.1016\/j.tranon. 2022.101374","DOI":"10.1016\/j.tranon.2022.101374"}],"container-title":["Recent Updates on Multiple Myeloma"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.intechopen.com\/download\/pdf\/85536","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T14:49:01Z","timestamp":1678891741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.intechopen.com\/chapters\/85536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,15]]},"ISBN":["9781803560922","9781803560939"],"references-count":83,"URL":"https:\/\/doi.org\/10.5772\/intechopen.109279","relation":{},"subject":[],"published":{"date-parts":[[2023,3,15]]}}}